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Thrombosis is generally considered harmful because it compromises the blood supply to organs. However, recent
studies have suggested that thrombosis under certain circumstances plays a major physiological role in early immune
defense against invading pathogens. This defensive role of thrombosis is now referred to as immunothrombosis.
Activated monocytes and neutrophils are two major inducers of immunothrombosis. Monocytes and neutrophils are
activated when they detect pathogen-associated molecular patterns (PAMPs) and damage-associated molecular
patterns (DAMPs). Detection of PAMPs and DAMPs triggers tissue factor expression on monocytes and neutrophil
extracellular trap (NET) release by neutrophils, promoting immunothrombosis. Although tissue factor-mediated
and NET-mediated immunothrombosis plays a role in early host defense against bacterial dissemination, uncontrolled
immunothrombosis may lead to disseminated intravascular coagulation.
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Blood must be maintained in a fluid state under physiologic
conditions, but then change to a solid state after vascular
injury. This balancing act is accomplished by platelets, co-
agulation factors, anticoagulant factors, fibrinolytic factors,
endothelial cells, and possibly leukocytes, which all support
the dynamic equilibrium that provides proper blood
flow [1]. Disruption of this well-regulated balance leads
to pathologic conditions, such as thrombosis and bleeding.Review
Basic mechanisms of hemostasis
Platelets and coagulation factors are two major players in
hemostasis. Platelets and coagulation factors circulate in
the blood and become activated at sites of vascular dam-
age. Platelets monitor vascular damage using cell-surface
sensors for subendothelial collagen and von Willebrand
factor bound to collagen. Engagement of the subendothe-
lial matrix by platelets results in a sequence of reactions
comprising platelet adhesion, activation, and aggregation,
leading to platelet thrombus formation [2]. CoagulationCorrespondence: takashi@m3.kufm.kagoshima-u.ac.jp
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unless otherwise stated.factors, more specifically coagulation factor VII, search for
sites of vascular damage where subendothelial tissue factor
is exposed. Binding of coagulation factor VIIa to tissue fac-
tor results in a cascade of blood-clotting reactions, leading
to thrombin generation and subsequent fibrin deposition
at sites of vascular damage (Figure 1). Platelet thrombus
formation and fibrin deposition occur concomitantly as
thrombin activates platelets, and activated platelets expose
phosphatidylserine on their membrane surface to provide
a scaffold for blood-clotting enzyme complexes [3].
In the hemostatic system, thrombin generation is trig-
gered by the factor VIIa-tissue factor complex, an inducer
of the so-called extrinsic pathway. Once small amounts of
thrombin are generated in this pathway, thrombin plays a
crucial role in the amplification and propagation phases of
coagulation, the so-called intrinsic pathway, by activating
coagulation factors V, VIII, and XI (Figure 1) [1]. This
leads to a burst of additional thrombin generation, which
is essential for forming sufficient fibrin and sealing the
sites of vascular damage. Coagulation factor XIII then
crosslinks fibrin fibers, a fundamental process for sta-
bilizing fibrin clots. Contact activation of coagulation
factor XII, another important trigger of coagulation in la-
boratory tests, is not considered essential for hemostasis
because hereditary deficiencies in factor XII are not asso-
ciated with abnormal bleeding [4,5]. However, factor XII
might be involved in pathological thrombosis [6-8] andOpen Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Basic mechanisms of coagulation. Coagulation factor VII searches for sites of vascular damage where subendothelial tissue factor is
exposed. Tissue factor is expressed on the surface of fibroblasts and pericytes in the subendothelial space. Binding of coagulation factor VIIa to
tissue factor results in a cascade of blood-clotting reactions, leading to thrombin generation (the initiation pathway). Once small amounts of
thrombin are generated in this pathway, thrombin plays a crucial role in the amplification and propagation phases of coagulation by activating
coagulation factors V, VIII, and XI (the amplification pathway). This leads to a burst of additional thrombin generation, which is essential for forming
sufficient fibrin and sealing the sites of vascular damage. Coagulation factor XIII then crosslinks fibrin fibers, a fundamental process for stabilizing fibrin
clots. Contact activation of coagulation factor XII, another important trigger of coagulation in laboratory tests, is not considered essential for hemostasis.
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thrombosis without affecting normal hemostasis [5].
The propagation of a hemostatic plug can be termi-
nated when it reaches intact endothelium. Endothelial
cells express several anticoagulants, including thrombo-
modulin (TM), tissue factor pathway inhibitor (TFPI),
and heparan sulfate (Figure 2) [9,10]. Upon binding to
TM, thrombin loses its ability to activate platelets, fi-
brinogen, and coagulation factors V, VIII, XI, and XIIIFigure 2 Anticoagulant properties of endothelial cells. Endothelial cells
factor pathway inhibitor (TFPI), and heparan sulfate. Upon binding to TM, thro
factors V, VIII, XI, and XIII. Furthermore, the thrombin-TM complex activate
coagulation factors Va and VIIIa. Endothelial cells also synthesize and disp
and antithrombin (AT), inhibiting the factor VIIa-tissue factor complex, fac[11]. Furthermore, the thrombin-TM complex activates
protein C, which in turn stops thrombin generation by
inactivating coagulation factors Va and VIIIa. Endothe-
lial cells also synthesize and display heparan sulfate
proteoglycans on their surface, which bind to TFPI and
antithrombin (AT), inhibiting the factor VIIa-tissue fac-
tor complex, factor Xa, and thrombin activity [10]. Thus,
endothelial cells play a role in regulating the spatial
localization of hemostatic plugs. Disruption of this well-express several anticoagulants, including thrombomodulin (TM), tissue
mbin loses its ability to activate platelets, fibrinogen, and coagulation
s protein C, which in turn stops thrombin generation by inactivating
lay heparan sulfate proteoglycans on their surface, which bind to TFPI
tor Xa, and thrombin activity. IIa thrombin, PS protein S.
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blood vessels (i.e., thrombosis) [1].
Immunothrombosis
Microvascular thrombosis is a frequent complication of
critical illness conditions, such as sepsis, trauma, and ma-
lignancy [12]. Thrombosis is generally considered harmful
because it compromises the blood supply to organs. How-
ever, recent studies have suggested that thrombosis under
certain circumstances plays a major physiological role in
immune defense [13,14]. This defensive role of thrombosis
is now referred to as immunothrombosis [13].
Thrombus formation and innate immunity are closely
linked [15]. Upon injury, multicellular organisms face two
major crises: bleeding and infection. To overcome these
crises, multicellular organisms have developed hemostatic
systems and immune systems. In horseshoe crabs, a single
hemocyte type circulates in their open circulatory system
and plays significant roles in both hemostasis and innate
immunity [16]. The hemocytes release procoagulant serine
protease zymogens when they detect lipopolysaccharide
(LPS) on their surface. The activation of these zymogens
triggers the coagulation cascade, which ultimately converts
coagulogen into insoluble coagulin gels [17]. Coagulin
clots are important not only for sealing injured sites but
also for trapping invading pathogens and supporting anti-
microbial defense. Thus, the hemocytes of horseshoe crabs
can detect and respond sensitively to LPS, maintaining
hemostasis and host defense against invading pathogens.
Horseshoe crab hemocytes are now used for laboratory
measurements of endotoxins.
Coagulation systems in mammals also play important
roles in immune defense. Fibrinogen-deficient mice display
impaired cytokine production, suppressed neutrophil re-
cruitment, increased bacterial burden, and increased mor-
tality after bacterial inoculation [18,19]. Furthermore, mice
pretreated with anticoagulants, such as coumadin or hiru-
din, also display increased bacterial burden and mortality
following bacterial inoculation [18,20]. These phenotypes
indicate protective roles of coagulation systems during
early host defense against bacterial dissemination. In
humans, coagulation systems are also activated during
infection [21]. However, it remains to be determined
whether anticoagulant therapy improves or worsens the
clinical outcomes of patients with infectious diseases.
Platelets have important roles in fighting infections.
Upon bacterial infection, platelets rapidly accumulate on
the surface of bacteria caught by Kupffer cells [22]. The
platelet-mediated encasement of bacteria restricts their
escape from Kupffer cells. This event precedes leukocyte
recruitment and contributes to early host defense against
infection in mice. Platelets are able to release antimicrobial
molecules and proinflammatory mediators, which may
further support host defense against infection [23]. Inhumans, thrombocytopenia is increasingly recognized as
an independent risk factor for serious infections [23].
Furthermore, antiplatelet therapy may be associated with
increased incidence of community-acquired pneumonia
[24], although it may also be associated with better out-
comes in patients with severe infections [25,26]. These
observations suggest that platelets may be important in
early host defense against invading pathogens before in-
fectious diseases develop but may be deleterious if in-
fections progress to severe forms with organ failure.
To date, four mechanistic models have been proposed for
how immunothrombosis provides protection against invad-
ing pathogens (Figure 3) [13]. First, immunothrombosis
limits microbial dissemination by retaining microbes within
thrombi. In this regard, coagulation factor XIII crosslinks
bacteria to fibrin fibers, leading to immobilization and kill-
ing of bacteria inside the clot [27]. Second, thrombi form
protective barricades inside and/or around blood vessels
that limit microbial movement in and out of the vessels
[20]. Third, fibrin, fibrinogen, and fibrin/fibrinogen deg-
radation products promote recruitment and activation of
leukocytes, such as neutrophils and macrophages, coord-
inating cellular immune responses to pathogens at sites of
infection [28]. Fourth, intravascular thrombi yield a dis-
tinct compartment where antimicrobial peptides are con-
centrated and have increased opportunities to come into
contact with pathogens. Antimicrobial peptides can be
released not only by leukocytes but also by platelets
and coagulation systems during the process of immu-
nothrombosis [23,29].Triggers for immunothrombosis
What are the triggers for immunothrombosis? During
the course of infections, platelets and coagulation factors
can become activated even in the absence of contact with
subendothelial collagen and tissue factor. It is now widely
believed that instead of subendothelial collagen and tissue
factor, neutrophils and monocytes could serve as the trig-
gers for immunothrombosis (Figure 4) [13].
Monocytes are a potential source of tissue factor in
circulating blood [30]. In contrast to subendothelial tissue
factor constitutively expressed on fibroblasts and pericytes,
monocyte-associated tissue factor expression is normally
very low and increases in response to pathogen stimuli
[31]. Genetic reduction of tissue factor expression on
leukocytes reduces LPS-induced thrombin generation
[32,33], suggesting that tissue factor on leukocytes acti-
vates coagulation in response to pathogen stimuli. Fur-
thermore, low tissue factor expression results in bacterial
dissemination and poor outcomes following bacterial
inoculation [18]. These findings indicate that monocyte-
associated tissue factor is an important inducer of
immunothrombosis.
Figure 3 Four mechanistic models explaining how immunothrombosis provides protection against invading pathogens. (1) Immunothrombosis
limits microbial dissemination by containing microbes within thrombi. (2) Thrombi form protective barricades inside and/or around blood vessels that limit
microbial movement in and out of the vessels. (3) Fibrin, fibrinogen, and fibrin/fibrinogen degradation products promote recruitment and activation of
leukocytes, such as neutrophils and macrophages, coordinating cellular immune responses to pathogens at sites of infection. (4) Intravascular thrombi yield
a distinct compartment where antimicrobial peptides are concentrated and have increased opportunities to come into contact with pathogens.
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are other inducers of immunothrombosis [13]. In response
to pathogen stimuli, neutrophils initiate a program involv-
ing rearrangement of the nuclear and granular architecture,
leading to extracellular release of NETs. NETs are com-
posed of web-like structures of DNA and antimicrobial
proteins such as histones, neutrophil elastase, and myelo-
peroxidase, and have the ability to entrap and kill microbes
[34,35]. NETs are also able to activate coagulation fac-
tor XII [8], inactivate anticoagulant TFPI [20], and pro-
vide a scaffold for platelet binding and aggregation [36],
all of which promote thrombus formation [37]. Block-
ade of NET activity by DNase or antibodies against
DNA-histone complexes results in decreased thrombus
formation [20,38,39] and increased microbial dissemination
[20,40-42], indicating that NETs play a critical role in
immunothrombosis.
PAMPs and DAMPs
As mentioned above, activated monocytes and neutro-
phils are two major inducers of immunothrombosis.
Therefore, the next question is what activates monocytes
and neutrophils to induce immunothrombosis?
Pathogen-associated molecular patterns (PAMPs) and
damage-associated molecular patterns (DAMPs) might
be responsible.The adaptive immune system composed of T and B
lymphocytes monitors non-self antigens using antigen-
specific receptors. Self-reactive lymphocytes are deleted
early in life, and residual lymphocytes establish a surveil-
lance system for non-self antigens. Although this system
is highly specific and effective for non-self antigen elimin-
ation, it is not perfect because immune responses against
harmless non-self components, such as fetuses or food-
stuffs, can be deleterious and should be avoided [43]. Innate
immune cells, including monocytes and neutrophils, em-
ploy a different surveillance system. They monitor common
molecular patterns of microbes (PAMPs) and/or molecules
from damaged cells of host origin (DAMPs) using pattern
recognition receptors (PRRs) and only activate the adaptive
immune system if they detect PAMPs and/or DAMPs.
Thus, the innate and adaptive immune systems develop a
mutually complementary relationship, and the overall im-
mune system constructs a surveillance system for infec-
tious non-self and/or damaging non-self antigens [43,44].
PAMPs, comprising molecular structures unique to
microbes, are subject to innate immune monitoring by
the host. For example, cell wall components, such as
LPS and β-glucan, or flagellar components, such as
flagellin, are recognized as PAMPs, and PAMP detec-
tion by PRRs triggers proinflammatory and antimicrobial
responses in innate immune cells [45]. PAMP detection
Figure 4 Triggers for immunothrombosis. Detection of PAMPs and DAMPs triggers NET release by neutrophils and tissue factor expression on
monocytes, promoting immunothrombosis. NETs are able to activate coagulation factor XII, inactivate anticoagulant TFPI, and provide a scaffold
for platelet binding and aggregation, all of which promote thrombus formation. A part of monocyte-associated tissue factor is released in the
form of microparticles and delivered into developing thrombi.
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[30,33] and NET release by neutrophils [38], promoting
immunothrombosis.
DAMPs are endogenous molecules that are normally
found inside cells, unless released by damage. Under nor-
mal conditions, DAMPs are hidden from recognition by
innate immune cells. However, under conditions of cellular
stress or injury, DAMPs can be released into the extracel-
lular space from damaged cells, activating innate immune
cells [46]. Prototypical DAMPs include nuclear proteins
such as high mobility group box 1 (HMGB1) [47,48] and
histones [49], purine metabolites such as ATP [50,51] and
uric acid [52,53], and mitochondrial components such as
formyl peptides and mitochondrial DNA [54]. Detection
of these DAMPs by PRRs, such as Toll-like receptors and
inflammasomes, triggers inflammation, which is important
for eradication of invading pathogens, clearance of dead
cells, and regeneration of damaged tissue [55]. DAMPs
also trigger intravascular thrombus formation [50], pos-
sibly by inducing tissue factor expression on monocytes
[56], elevating tissue factor procoagulant activity [57,58],
and promoting platelet aggregation [59].
Immunothrombosis beyond control
Although immunothrombosis might be important in early
host defense against bacterial dissemination, uncontrolled
immunothrombosis might be detrimental to the host.Disseminated intravascular coagulation (DIC) occurs in
25%–50% of patients with sepsis and is associated with
poor outcomes [12,60]. DIC is characterized by widespread
microvascular thrombosis with exhaustion of coagulation
factors and platelets [61]. Monocyte-associated tissue
factor and neutrophil-derived NETs are predisposing
factors for DIC [20,32,38,40,62], indicating that DIC
might be an advanced stage of immunothrombosis wherein
the immune system is no longer able to restrict PAMP/
DAMP spreading and immunothrombosis becomes over-
whelmed [13].
As mentioned above, tissue factor-induced coagulation
is important for preventing bacterial dissemination [18].
However, excessive coagulopathy can be detrimental [63],
and pharmacological inhibition of tissue factor or genetic
reduction of tissue factor expression often rescues animals
from sepsis-associated lethal coagulopathy [32,33,62]. Simi-
larly, elimination of NETs can decrease organ damage
[38,40], although NETs are important for preventing
bacterial dissemination [40-42]. These findings support
the concept that immunothrombosis can be detrimental
if it becomes overwhelmed.
The same is true for DAMPs. Although DAMPs have
beneficial roles in immunity and tissue repair [44,64], ex-
cessive DAMPs can be detrimental. Serum and plasma
HMGB1 levels are elevated in patients with sepsis and/or
DIC [65,66] and are correlated with DIC scores.
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sion on monocytes, inhibits protein C activation, and
promotes microvascular thrombosis development [56].
Antibodies or antagonists capable of neutralizing HMGB1
reduce organ damage and improve survival of septic mice
[65,67,68], indicating that excessive HMGB1 circulating in
the blood is detrimental. Plasma histone levels are also ele-
vated in patients with sepsis and DIC [69,70]. Extracellular
histones trigger platelet aggregation, fibrin deposition,
thrombotic occlusion of microvessels, and exhaustion of
coagulation factors and platelets [70]. Extracellular
cell-free DNA (cfDNA) also acts as a DAMP [71]. Plasma
cfDNA levels are elevated in patients with severe sepsis, es-
pecially in non-survivors and have better prognostic utility
than Acute Physiology and Chronic Health Evaluation
(APACHE) II scores, Multiple Organ Failure Assessment
(SOFA) scores, and other biomarkers [72]. The majority of
plasma cfDNA is derived from the host [72,73], although
some originates from bacteria, fungi, and viruses. cfDNA is
the major structural component of NETs, and cfDNA/
NETs can promote thrombin generation, in part, through
activation of coagulation factor XII [39,74]. Depletion of
cfDNA/NETs by DNase treatment impedes early immune
responses [75], suggesting that cfDNA-mediated immuno-
thrombosis might be important in early host defense
against bacterial dissemination.
In septic conditions, the procoagulant-anticoagulant
balance becomes disturbed. While tissue factor- and NET-
associated procoagulant activity is increased during sepsis,
anticoagulant proteins, such as TM, protein C, and AT,
can be severely compromised [60,76-78]. Furthermore,
fibrinolysis is attenuated in septic conditions, in part
through increased plasminogen activator inhibitor type-1
(PAI-1) release from endothelial cells [60]. Thus, disturb-
ance of the procoagulant-anticoagulant balance, with
increases in procoagulant tissue factor and NETs and
decreases in anticoagulants and fibrinolytic capacity, is
the key feature of sepsis-associated DIC.
Therapeutic options for DIC
The cornerstone for managing DIC remains the manage-
ment of the underlying causes, such as sepsis, in most
Western countries [61]. Accordingly, there is no mention
of DIC in the Surviving Sepsis Campaign guidelines, com-
prising international guidelines for management of severe
sepsis and septic shock [79]. Consequently, anticoagulant
drugs might be used for the treatment of sepsis, but not
for DIC itself in those countries.
Activated protein C (APC) is a natural anticoagulant that
can dampen thrombin generation by inactivating coagula-
tion factors Va and VIIIa (Figure 2). APC also exerts cyto-
protective effects, in part through activation of endothelial
cell protease-activated receptor 1 [80]. Drotrecogin alfa
(activated), a recombinant human APC (rhAPC), used tobe the only approved drug associated with significantly im-
proved survival of patients with severe sepsis, based on a
large-scale, randomized, double-blind, placebo-controlled,
multicenter trial (PROWESS study) [81]. However, the ini-
tial success was not replicated in subsequent trials of dro-
trecogin alfa (activated) in patients with severe sepsis and
low risk of death [82], children with severe sepsis [83], and
patients with septic shock [84], and this drug has now been
withdrawn from the market [85]. Possible reasons for this
failure include the increased risk of serious bleeding in the
rhAPC group and lower placebo mortality rates compared
with the original PROWESS study, making it difficult to
demonstrate beneficial effects of rhAPC.
TM is an anticoagulant cofactor that converts throm-
bin into an APC generator (Figure 2). Because TM is es-
sential for preventing intravascular coagulation [86] and
its expression is compromised during sepsis [76], substi-
tution with recombinant human soluble TM (rhsTM) is
a promising treatment for patients with sepsis and DIC.
Although the anticoagulant action of TM is mainly medi-
ated by APC, rhsTM treatment may have some advantages
over rhAPC. First, rhsTM may have less risk of bleeding
complications than rhAPC because it is a cofactor and
does not act as an anticoagulant when no thrombin exists
[87]. Second, the APC-independent actions of rhsTM
might confer a benefit. These actions include sequestra-
tion of PAMPs [88], DAMPs [68,70,89], and comple-
ments [90] through the lectin-like domain of rhsTM [91].
In a randomized, double-blind, parallel-group trial to evalu-
ate DIC resolution rates, rhsTM was significantly superior
to heparin for DIC improvement [92]. The 28-day mortality
rates were assessed as a secondary endpoint in the study
and were 28.0% for the rhsTM group and 34.6% for the
heparin group (difference: −6.6%; 95% CI: −24.6 to 11.3) in
patients with DIC and infection. Thus, rhsTM has been
approved in Japan for treatment of DIC, although fur-
ther studies are needed to confirm that rhsTM improves
clinical outcomes in patients with sepsis-associated DIC.
Post-marketing retrospective observational studies sug-
gested that rhsTM therapy might be associated with better
outcomes [93-95], and an international, multicenter, ran-
domized, double-blind, placebo-controlled, phase 3 clinical
trial for rhsTM is now in progress. Severe sepsis patients
with coagulopathy are scheduled to be evaluated in this
trial, on the grounds that mortality rates of sepsis patients
without organ dysfunction are relatively low and it is thus
difficult to evaluate treatment benefits on mortality in these
patients, and that patients with coagulopathy might gain
greater benefits from anticoagulant therapy [96].
AT is the most abundant anticoagulant protein circu-
lating in the blood. AT is rapidly depleted in the early
phases of sepsis through decreased synthesis, increased de-
struction, and enhanced clearance by thrombin-AT com-
plex (TAT) formation [77,78]. AT has anti-inflammatory
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anticoagulant activity of AT but may diminish anti-
inflammatory effects of AT [97]. The effects of high-dose
AT treatment in patients with severe sepsis were inves-
tigated in the KyberSept trial, a large-scale, randomized,
double-blind, placebo-controlled, phase 3 clinical trial
[98]. However, it showed that high-dose AT had no effect
on 28-day all-cause mortality and was associated with in-
creased risk of hemorrhage when administered with
heparin. There is some evidence to suggest treatment ben-
efits of AT in subgroups of patients not receiving con-
comitant heparin and complicated with DIC [98-100]. The
efficacy and safety of AT need to be confirmed in further
studies.Conclusions
Immunothrombosis plays an important role in early im-
mune defense against invading pathogens. DIC is consid-
ered to be an advanced stage of immunothrombosis, where
the immune system is no longer able to restrict PAMP/
DAMP spreading and immunothrombosis becomes over-
whelmed. In this stage, thrombosis is detrimental because
it causes multiple organ failure. Although anticoagulant
drugs, such as APC, TM, and AT, are promising options
for treatment of sepsis-associated DIC, none of them have
been shown to improve the outcomes of patients with
sepsis. The key to success may be the selection of proper
patients, proper timing, and proper dosages.
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